Vasopressin in septic shock: Clinical equipoise mandates a time for restraint

Critical Care Medicine

Volumn 31, Issue 11, 2003, Pages 2707-2709

  Russell, James A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiac output; Human septic shock; Norepinephrine; Spalchnic blood flow; Vasopressin

Indexed keywords

NORADRENALIN; VASOPRESSIN;

ARTERIAL CARBON DIOXIDE TENSION; BLOOD PRESSURE REGULATION; DOSE TIME EFFECT RELATION; EDITORIAL; HUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SEPTIC SHOCK; SPLANCHNIC BLOOD FLOW;

BLOOD PRESSURE; CLINICAL TRIALS; HUMANS; NOREPINEPHRINE; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 0344874150     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000092458.16716.EE     Document Type: Editorial

References (22)

1. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125
2. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001; 27: 1416-1421
3. Patel BM, Chittock DR, Russell JA, et al: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582
4. Landry DW, Levin HR, Gallant EM, et al: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25: 1279-1282
5. Malay MB, Ashton RC Jr, Landry DW, et al: Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47: 699-705
6. Argenziano M, Choudhri AF, Oz MC, et al: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96:II-286-II-290
7. Argenziano M, Chen JM, Choudhri AF, et al: Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116:973-980
8. Argenziano M, Chen JM, Cullinane S, et al: Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 1999; 18:814-817
9. Rosenzweig EB, Starc TJ, Chen JM, et al: Intravenous arginine- vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999; 100:II182-II186
10. Morales DL, Gregg D, Helman DN, et al: Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000; 69:102-106
11. Chen JM, Cullinane S, Spanier TB, et al: Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 1999; 100: II244-II246
12. Gold JA, Cullinane S, Chen J, et al: Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 2000; 28:249-252
13. Klinzing S, Simon M, Reinhart K, et al: High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31:2646-2650
14. Martin C, Papazian L, Perrin G, et al: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826-1831
15. Landry DW, Oliver JA: The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992; 89:2071-2074
16. Schwartz J, Reid IA: Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology 1981; 109:1778-1780
17. Wakatsuki T, Nakaya Y, Inoue I: Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 1992; 263: H491-H496
18. Thibonnier M, Preston JA, Dulin N, et al: The human V3 pituitary vasopressin receptor: Ligand binding profile and density-dependent signaling pathways. Endocrinology 1997; 138:4109-4122
19. Vanhoutte PM, Katusic ZS, Shepherd JT: Vasopressin induces endothelium-dependent relaxations of cerebral and coronary, but not of systemic arteries. J Hypertens Suppl 1984; 2:S421-S422
20. Edwards RM, Trizna W, Kinter LB: Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989; 256:F274-F278
21. Takala J, Ruokenen E, Webster NR, et al: Increased mortality associated with growth hormone treatment in the critically ill. N Engl J Med 1999; 341:785-792
22. Grover R, Lopez A, Lorente J, et al: Multicenter, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 1999; 27(Suppl):A33